Psoriasis News and Research

Latest Psoriasis News and Research

Thirteen scientists receive grant to identify new treatments, cure for psoriasis

Thirteen scientists received a total of $1.05 million in funding from the National Psoriasis Foundation for projects that aim to identify new treatments and a cure for psoriasis—an autoimmune disease that appears on the skin, affecting 7.5 million Americans—and psoriatic arthritis—an inflammatory arthritis that affects the joints and tendons, occurring in up to 30 percent of people with psoriasis.

16 Jul 2014

Johnson & Johnson sales increase 9.1% to $19.5 billion in second quarter 2014

Johnson & Johnson today announced sales of $19.5 billion for the second quarter of 2014, an increase of 9.1% as compared to the second quarter of 2013. Operational results increased 9.4% and the negative impact of currency was 0.3%.

15 Jul 2014

Metvix PDT now available at Odette Cancer Centre as additional treatment option for NMSC patients

The Odette Cancer Centre at Sunnybrook Health Sciences Centre in conjunction with Galderma Canada are pleased to announce that Metvix PDT (Photodynamic Therapy), is now available at the Odette Cancer Centre in Toronto as an additional treatment option for patients with NMSC (non-melanoma skin cancer).

15 Jul 2014

Medac Pharma's Rasuvo injection gets FDA approval for RA, pJIA and psoriasis

Medac Pharma, Inc., a privately held pharmaceutical company focused on the development of new molecules and improving the effectiveness of existing medicines, announced that the U.S. Food and Drug Administration has approved Rasuvo, a subcutaneous injectable methotrexate (MTX) therapy delivered in an auto-injector for rheumatoid arthritis (RA), polyarticular-course juvenile idiopathic arthritis (pJIA) and psoriasis.

14 Jul 2014

Dmitry Medvedev presents Russia's first national "Industry" award to BIOCAD

On July 9 Prime Minister of the Russian Federation Dmitry Medvedev, presented Russia's first national "Industry" award to a biopharmaceutical company BIOCAD.

11 Jul 2014

National Psoriasis Foundation to double the number of researchers studying psoriasis

National Psoriasis Foundation will double the number of researchers studying psoriasis and psoriatic arthritis while also cutting in half the number of people who say these chronic conditions are a problem in their daily lives as part of its new five-year strategic plan and mission to cure psoriatic disease and improve the lives of those affected.

10 Jul 2014

Can-Fite's CF102 drug gets approval in Israel for patient with hepatocellular carcinoma

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that the Israeli Ministry of Health has approved the use of its drug CF102 for a patient with hepatocellular carcinoma, the most common form of liver cancer, under the country's Compassionate Use Program.

10 Jul 2014

New diagnostic procedure helps differentiate psoriasis from eczema

In some patients, the chronic inflammatory skin diseases psoriasis* and eczema** are similar in appearance. Up to now, dermatologists have therefore had to base their decision on which treatment should be selected on their own experience and an examination of tissue samples.

10 Jul 2014

UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

UCB, a global biopharmaceutical leader, and Dermira, Inc., a privately held US-based dermatology company, announced today that they have entered into an exclusive licensing agreement for the development and future commercialization of Cimzia (certolizumab pegol) in dermatology.

3 Jul 2014

Hypertension, antihypertensive medications may increase risk of psoriasis in women

Women with long-term high blood pressure (hypertension) appear to be at an increased risk for the skin condition psoriasis, and long-term use of beta (β)-blocker medication to treat hypertension may also increase the risk of psoriasis.

3 Jul 2014

Galderma's trifarotene molecule gets FDA Orphan Drug Designation for treatment of congenital ichthyosis

Galderma announces that the U.S. FDA granted Orphan Drug Designation status for the company's trifarotene molecule for the treatment of congenital ichthyosis. Based on this decision, Galderma plans to implement a clinical development plan, reinforcing its commitment to exploring new treatment options for rare diseases, as well as meeting the needs of all patients with skin diseases over the course of their lives.

2 Jul 2014

Janssen seeks expanded approval of VELCADE from EU for Mantle Cell Lymphoma

Janssen-Cilag International NV today announced its submission of a type II variation to the European Medicines Agency to expand the label for VELCADE (bortezomib) to include its use, in combination with rituximab, cyclophosphamide, doxorubicin and prednisone, for the treatment of adult patients with previously untreated Mantle Cell Lymphoma (MCL).

28 Jun 2014

XenoPort initiates XP23829 Phase 2 clinical trial in patients with psoriasis

XenoPort, Inc. announced today that it has initiated a Phase 2 clinical trial of XP23829, its proprietary investigational next-generation fumaric acid product candidate. The trial is a multi-center, randomized, double-blind, placebo-controlled study designed to assess the efficacy and safety of XP23829 as a potential treatment of patients with moderate-to-severe chronic plaque-type psoriasis.

23 Jun 2014

Arthritis drug promotes hair growth in hairless man

A man with almost no hair on his body has grown a full head of it after a novel treatment by doctors at Yale University.

20 Jun 2014

3SBio signs exclusive license agreement with Selecta Biosciences for pegsiticase

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive license with Selecta Biosciences for pegsiticase (Uricase PEG-20), a pegylated recombinant uricase from candida utilis.

18 Jun 2014

One-third of PsA patients not receiving adalimumab doses to achieve optimal clinical benefit

Data presented today at the European League Against Rheumatism Annual Congress showed that a significant number of patients with psoriatic arthritis (PsA) were not receiving doses of the tumour necrosis factor-alpha (TNFα) inhibitor adalimumab necessary to achieve optimal clinical benefit.

12 Jun 2014

Celgene: OTEZLA phase III study for psoriatic arthritis meets primary endpoint

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG), today announced results of additional analyses from the phase III clinical trials of OTEZLA, the Company's oral, selective inhibitor of phosphodiesterase 4 (PDE4).

11 Jun 2014

AbbVie's ALIGN study underscores patients’ attitudes and adherence toward TNF inhibitors

AbbVie today announced results from its multi-country ALIGN study, which shows that across six chronic immune-mediated inflammatory diseases (IMIDs), adherence to treatment was generally higher in patients being treated with TNF inhibitors compared to patients treated with conventional therapy.

11 Jun 2014

Tolero Pharmaceuticals reports positive interim results from alvocidib Phase 2 trial for AML treatment

Tolero Pharmaceuticals, Inc., a late clinical-stage biopharmaceutical company developing treatments for oncology and blood disorders, reported positive interim results from an ongoing, randomized Phase 2 clinical trial of its lead drug candidate, alvocidib, in combination with cytarabine plus mitoxantrone for previously untreated acute myeloid leukemia (AML) patients.

6 Jun 2014

Provectus’ PV-10 data for intralesional treatment of solid tumors presented at ASCO annual meeting

Provectus Biopharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that data on its investigational agent PV-10 for intralesional (IL) treatment of solid tumors were featured in two presentations in the Poster Highlights Session, Melanoma/Skin Cancers, on June 2, 2014 during the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, IL.

4 Jun 2014

Psoriasis News and Research

Latest Psoriasis News and Research

Thirteen scientists receive grant to identify new treatments, cure for psoriasis

Johnson & Johnson sales increase 9.1% to $19.5 billion in second quarter 2014

Metvix PDT now available at Odette Cancer Centre as additional treatment option for NMSC patients

Medac Pharma's Rasuvo injection gets FDA approval for RA, pJIA and psoriasis

Dmitry Medvedev presents Russia's first national "Industry" award to BIOCAD

National Psoriasis Foundation to double the number of researchers studying psoriasis

Can-Fite's CF102 drug gets approval in Israel for patient with hepatocellular carcinoma

New diagnostic procedure helps differentiate psoriasis from eczema

UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

Hypertension, antihypertensive medications may increase risk of psoriasis in women

Galderma's trifarotene molecule gets FDA Orphan Drug Designation for treatment of congenital ichthyosis

Janssen seeks expanded approval of VELCADE from EU for Mantle Cell Lymphoma

XenoPort initiates XP23829 Phase 2 clinical trial in patients with psoriasis

Arthritis drug promotes hair growth in hairless man

3SBio signs exclusive license agreement with Selecta Biosciences for pegsiticase

One-third of PsA patients not receiving adalimumab doses to achieve optimal clinical benefit

Celgene: OTEZLA phase III study for psoriatic arthritis meets primary endpoint

AbbVie's ALIGN study underscores patients’ attitudes and adherence toward TNF inhibitors

Tolero Pharmaceuticals reports positive interim results from alvocidib Phase 2 trial for AML treatment

Provectus’ PV-10 data for intralesional treatment of solid tumors presented at ASCO annual meeting

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Psoriasis News and Research

Latest Psoriasis News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in